These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

571 related articles for article (PubMed ID: 32170458)

  • 21. Prognostic markers and standard management of chronic lymphocytic leukemia.
    Stilgenbauer S
    Hematology Am Soc Hematol Educ Program; 2015; 2015():368-77. PubMed ID: 26637745
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination of Targeted Drugs to Control Chronic Lymphocytic Leukemia: Harnessing the Power of New Monoclonal Antibodies in Combination With Ibrutinib.
    Cramer P; Langerbeins P; Hallek M
    Cancer J; 2016; 22(1):62-6. PubMed ID: 26841018
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Current diagnosis and treatment of chronic lymphocytic leukaemia].
    Cramer P; von Tresckow J; Eichhorst B; Hallek M
    Dtsch Med Wochenschr; 2020 Aug; 145(16):1139-1144. PubMed ID: 32791549
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chronic Lymphocytic Leukemia: Chemotherapy Free and Other Novel Therapies Including CAR T.
    Wiedmeier-Nutor J; Leis J
    Curr Treat Options Oncol; 2022 Jun; 23(6):904-919. PubMed ID: 35435617
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015.
    Zelenetz AD; Gordon LI; Wierda WG; Abramson JS; Advani RH; Andreadis CB; Bartlett N; Byrd JC; Czuczman MS; Fayad LE; Fisher RI; Glenn MJ; Habermann TM; Harris NL; Hoppe RT; Horwitz SM; Kelsey CR; Kim YH; Krivacic S; LaCasce AS; Nademanee A; Porcu P; Press O; Rabinovitch R; Reddy N; Reid E; Saad AA; Sokol L; Swinnen LJ; Tsien C; Vose JM; Wilson L; Yahalom J; Zafar N; Dwyer M; Sundar H;
    J Natl Compr Canc Netw; 2015 Mar; 13(3):326-62. PubMed ID: 25736010
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current Approaches and Novel Agents in the Treatment of Chronic Lymphocytic Leukemia.
    Cheson BD; Sharman JP
    JCO Oncol Pract; 2024 Oct; 20(10):1360-1366. PubMed ID: 38848511
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictive and prognostic biomarkers in the era of new targeted therapies for chronic lymphocytic leukemia.
    Rossi D; Gerber B; Stüssi G
    Leuk Lymphoma; 2017 Jul; 58(7):1548-1560. PubMed ID: 27808579
    [TBL] [Abstract][Full Text] [Related]  

  • 28. How to Choose the Best Treatment and Testing for Chronic Lymphocytic Leukemia in the Tsunami of New Treatment Options.
    Yeung CCS; Shadman M
    Curr Oncol Rep; 2019 Jul; 21(8):74. PubMed ID: 31327069
    [TBL] [Abstract][Full Text] [Related]  

  • 29. How and when I do allogeneic transplant in CLL.
    Gribben JG
    Blood; 2018 Jul; 132(1):31-39. PubMed ID: 29752258
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of chronic lymphocytic leukemia.
    Stilgenbauer S; Furman RR; Zent CS
    Am Soc Clin Oncol Educ Book; 2015; ():164-75. PubMed ID: 25993154
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current perspectives on the role of chemotherapy in chronic lymphocytic leukemia.
    Wendtner CM; Gregor M
    Leuk Lymphoma; 2018 Feb; 59(2):300-310. PubMed ID: 28565930
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An evaluation of zanubrutinib, a BTK inhibitor, for the treatment of chronic lymphocytic leukemia.
    Geethakumari PR; Awan F
    Expert Rev Hematol; 2020 Oct; 13(10):1039-1046. PubMed ID: 32869675
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The combination of venetoclax and rituximab for the treatment of patients with recurrent chronic lymphocytic leukemia.
    Vitale C; Ferrajoli A
    Expert Rev Hematol; 2020 Aug; 13(8):885-894. PubMed ID: 32700593
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [State of the art molecular diagnostics and therapy of chronic lymphocytic leukaemia in the era of new targeted therapies].
    Gurbity Pálfi T; Fésüs V; Bödör C; Borbényi Z
    Orv Hetil; 2017 Oct; 158(41):1620-1629. PubMed ID: 29025288
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The evolving treatment landscape of chronic lymphocytic leukemia.
    Schiattone L; Ghia P; Scarfò L
    Curr Opin Oncol; 2019 Nov; 31(6):568-573. PubMed ID: 31593975
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of elderly and unfit patients with chronic lymphocytic leukemia.
    Mauro FR; Salaroli A; Caputo MD; Colafigli G; Petrucci L; Campanelli M; Ferretti A; Guarini AR; Foà R
    Expert Rev Hematol; 2016 Dec; 9(12):1165-1175. PubMed ID: 27796157
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Frontline Therapy of Chronic Lymphocytic Leukemia: Changing Treatment Paradigm.
    Sengar M; Jain H; Rajendra A; Rengaraj K; Thorat J
    Curr Hematol Malig Rep; 2020 Jun; 15(3):168-176. PubMed ID: 32542586
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients.
    Mato AR; Hill BT; Lamanna N; Barr PM; Ujjani CS; Brander DM; Howlett C; Skarbnik AP; Cheson BD; Zent CS; Pu JJ; Kiselev P; Foon K; Lenhart J; Henick Bachow S; Winter AM; Cruz AL; Claxton DF; Goy A; Daniel C; Isaac K; Kennard KH; Timlin C; Fanning M; Gashonia L; Yacur M; Svoboda J; Schuster SJ; Nabhan C
    Ann Oncol; 2017 May; 28(5):1050-1056. PubMed ID: 28453705
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting BTK in CLL: Beyond Ibrutinib.
    Bond DA; Woyach JA
    Curr Hematol Malig Rep; 2019 Jun; 14(3):197-205. PubMed ID: 31028669
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of Chronic Lymphocytic Leukemia With del(17p)/TP53 Mutation: Allogeneic Hematopoietic Stem Cell Transplantation or BCR-Signaling Inhibitors?
    Montserrat E; Dreger P
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S74-81. PubMed ID: 27521330
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.